SYNLOGIC, INC. — fact timeline

SYNLOGIC, INC. received a nasdaq delisting notice notice regarding other.

“January 16, 2026. As a result, on January 16, 2026, the Company received notice from Nasdaq that its shares will be suspended at the open of business on January 21, 2026. Nasdaq is expected to file a Form 25 Notification of Delisting with the Securities Exchange Commission when all internal procedural periods have run. The Company expects and plans for its shares of common stock to be quoted by the OTC Markets Group, Inc. (“OTC”) upon being delisted from Nasdaq. The Company will continue to remain a reporting company under the Securities Exchange Act of 1934, as amended, and the transition to”

SYNLOGIC, INC. received a nasdaq delisting notice notice regarding other.

“November 21, 2025, Synlogic, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that stated the Staff’s belief that the Company is a “public shell” and that, therefore, the continued listing of its securities is no longer warranted in the view of the Staff. In the Notice, the Staff explained that it based this belief on its review of the Company’s public disclosures and materials submitted to the Staff by the Company. In addition, the Staff noted its belief is supported by the Company’s lack o”

Michael Heffernan resigned as member of the board of directors at SYNLOGIC, INC..

“On February 20, 2025, Michael Heffernan tendered his resignation as a member of the board of directors (the “Board”) of Synlogic, Inc. (the “Company”) and as a member of the audit committee and nominating and governance committee of the Board, effective immediately.”

Nick Leschly resigned as Director at SYNLOGIC, INC..

“On January 10, 2025, Nick Leschly tendered his resignation as a member of the board of directors (the “Board”) of Synlogic, Inc. (the “Company”) and as a member of the compensation committee of the Board, effective immediately.”

SYNLOGIC, INC. reported the quarter ended March 31, 2024 results: revenue $0.01 million, net income consolidated net loss of $31.6 million, or $2.60 per share, EPS $2.60 per share.

“transaction. First Quarter 2024 Financial Results As of March 31, 2024 Synlogic had cash, cash equivalents, and short-term marketable securities of $32.3 million. Revenue was $0.01 million for the three months ended March 31, 2024, compared to $0.2 million for the corresponding period in 2023. Revenue for the three months ended March 31, 2024 was related to a”

Patricia N. Hurter resigned as Director at SYNLOGIC, INC..

“On March 20, 2024, Patricia N. Hurter, Ph.D. notified the Board of her decision to resi”

Lisa Kelly-Croswell resigned as Director at SYNLOGIC, INC..

“On March 20, 2024, Lisa Kelly-Croswell notified the Board of her decision to resign from the Board and the Compensation Committee as well as the Nominating and Governance Committee, effective immediately.”

Mike Burgess resigned as Director at SYNLOGIC, INC..

“On March 20, 2024, Mike Burgess, MB, CHB, Ph.D notified the Board of his decision to resign from the Board and the Audit Committee and the Science and Technology Committee, effective immediately.”

James Flynn was appointed as Class I Director at SYNLOGIC, INC..

“appointed James Flynn effective March 19, 2024 (the “Effective Date”), as a director to the Board to serve as a Class I Director”

SYNLOGIC, INC. reported the year ended December 31, 2023 results: revenue $3.4 million, net income $57.3 million, EPS $8.81 per share.

“$1.71 per share, compared to a consolidated net loss of $16.7 million, or $3.54 per share, for the corresponding period in 2022. Full Year 2023 Financial Results Revenues were $3.4 million for the year ended December 31, 2023, compared to $1.2 million for the same period in 2022. Revenue in both periods was associated with the research collaboration with Roche.”

SYNLOGIC, INC. reported the quarter ended December 31, 2023 results: revenue $2.8 million, net income $14.5 million, EPS $1.71 per share.

“Company. Fourth Quarter 2023 Financial Results As of December 31, 2023, Synlogic had cash, cash equivalents, and short-term marketable securities of $47.7 million. Revenue was $2.8 million for the three months ended December 31, 2023, compared to $0.1 million for the corresponding period in 2022. Revenue in both periods was associated with the research”

Antoine Awad departed as Chief Operating Officer at SYNLOGIC, INC..

“Mr. Awad’s employment with the Company will end on May 30, 2024”

Aoife Brennan was terminated as President and Chief Executive Officer at SYNLOGIC, INC..

“Synlogic, Inc. (the “ Company ”) and Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, agreed that Dr. Brennan’s employment with the Company will terminate effective March 9, 2024”

SYNLOGIC, INC.: Filed Certificate of Designations for Series A Junior Participating Preferred Stock in connection with adoption of Rights Agreement (effective 2024-02-20).

“In connection with the adoption of the Rights Agreement, on February 20, 2024, the Company filed a Certificate of Designations, Preferences and Rights of Series A Junior Participating Preferred Stock (the “Certificate of Designations”), with the Secretary of State of the State of Delaware.”

SYNLOGIC, INC. entered into Rights Agreement with Equiniti Trust Company LLC (effective 2024-02-20).

“the Company entered into a Rights Agreement (the “Rights Agreement”), dated as of February 20, 2024, between the Company and Equiniti Trust Company LLC, as rights agent.”

SYNLOGIC, INC. announced a restructuring with charges of approximately $6 million affecting corporate (approximately 90%).

“On February 8, 2024, the Company announced that it is implementing a reduction in workforce by approximately 90%. The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options. The Company expects to complete substantially all of the reduction in workforce by the end of the fiscal quarter ending March 31, 2024. The Company estimates that it will incur approximately $6 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.”

Aoife Brennan resigned as Director at SYNLOGIC, INC..

“Dr. Brennan also resigned from the Company’s Board of Directors, effective March 9, 2024.”

Aoife Brennan was terminated as President and Chief Executive Officer at SYNLOGIC, INC..

“the Company and Aoife Brennan, M.B. Ch.B., the Company’s President and Chief Executive Officer, agreed on February 8, 2024 that Dr. Brennan’s employment with the Company will terminate effective as of March 9, 2024.”

Michael Jensen resigned as Chief Financial Officer at SYNLOGIC, INC..

“On November 13, 2023, Michael Jensen, Chief Financial Officer of Synlogic, Inc. (the “Company”) resigned from his role as Chief Financial Officer of the Company, effective December 1, 2023 (the “Departure Date”).”

SYNLOGIC, INC. reported the quarter ended September 30, 2023 results: revenue $0.4 million, net income $12.1 million, or $2.57 per share, EPS $2.57 per share.

“$19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration announced in November. Revenue for the three months ended September 30, 2023 was $0.4 million compared to $0.7 million for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the”

SYNLOGIC, INC. entered into Underwriting Agreement with Chardan Capital Markets, LLC (effective 2023-09-28).

“On September 28, 2023, Synlogic, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Chardan Capital Markets, LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell 3,921,928 shares of its common stock (the “Shares”), pre-funded warrants to purchase up to 3,472,435 shares of its common stock (the “Pre-Funded Warrants”) and accompanying common stock warrants to purchase up to 7,394,363 shares of its common stock (the “Purchase Warrants”) to the Underwriter (the “Offering”).”

SYNLOGIC, INC.: Reverse stock split of common stock at a ratio of 1-for-15 via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-09-27).

“On September 27, 2023, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to effect a one-time reverse stock split of the Company’s common stock, at a ratio of 1-for-15 (the “Reverse Stock Split”). The Reverse Stock Split was effective at 5:00 p.m. Eastern Time, after the close of trading on The Nasdaq Capital Market, on September 27, 2023”

SYNLOGIC, INC. shareholders approved Approval of an adjournment of the special meeting to solicit additional proxies if necessary to adopt Proposal 1 at the 2023-09-21 meeting.

“Proposal 2 The Company’s stockholders approved an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1. Votes For Votes Against Votes Abstained 47,228,190 782,326 226,781”

SYNLOGIC, INC. shareholders approved Approval of an amendment to the certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-5 and not more than 1-for-15 at the 2023-09-21 meeting.

“Proposal 1 The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of not less than 1-for-5 and not more than 1-for-15, with the exact ratio to be set within that range at the discretion of the Company’s Board of Directors (the “Board”) without further approval or authorization of the Company’s stockholders and with the Board able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion. Votes For Votes Against Votes Abstained 46,381,445 1,117,575 738,277”

SYNLOGIC, INC. amended Amendment to Pilot Collaboration and Option Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (effective 2023-08-16).

“On August 16, 2023, Synlogic Operating Company, Inc. (“Synlogic OpCo”), a wholly-owned subsidiary of Synlogic, Inc. (the “Company”), F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US”, and together with Roche Basel, “Roche”) entered into an amendment (the “Amendment”) to the Pilot Collaboration and Option Agreement (the “Roche Collaboration and Option Agreement”), effective as of June 16, 2021, by and between Synlogic OpCo and Roche.”

SYNLOGIC, INC. reported the quarter ended June 30, 2023 results: revenue $35 thousand, net income consolidated net loss of $15.0 million, or $0.21 per share.

“2023 Financial Results and Financial Outlook As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the”

SYNLOGIC, INC.: Added Article X to the Amended and Restated Certificate of Incorporation to permit exculpation of officers for breaches of fiduciary duty of care (effective 2023-06-15).

“The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Synlogic, Inc. with the Secretary of State of Delaware on June 15, 2023”

SYNLOGIC, INC. shareholders approved Approval of an amendment to the Amended and Restated Certificate of Incorporation to add a new Article X to permit exculpation of officers at the 2023-06-15 meeting.

“4. The Company’s stockholders approved the proposed amendment to the Company’s Amended and Restated Certificate of Incorporation, as disclosed in the Proxy Statement, based on the following votes: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Votes 48,468,332 496,262 204,603 10,190,664”

SYNLOGIC, INC. shareholders approved Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for fiscal year 2023 at the 2023-06-15 meeting.

“3. The selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified, based on the following votes: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Votes 59,077,771 31,856 250,234 —”

SYNLOGIC, INC. shareholders approved Advisory vote to approve the compensation of the Company's named executive officers at the 2023-06-15 meeting.

“2. The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, based on the following votes: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Votes 48,309,989 619,243 239,965 10,190,664”

SYNLOGIC, INC. shareholders approved The following nominees were reelected to serve on the Company’s board of directors (the “Board of Directors”) as Class II directors until the Company’s 2026 annual meeting of stockholders at the 2023-06-15 meeting.

“1. The following nominees were reelected to serve on the Company’s board of directors (the “Board of Directors”) as Class II directors until the Company’s 2026 annual meeting of stockholders, based on the following votes: Nominee Shares Voted For Shares Voted to Withhold Authority Broker Non-Vote Peter Barrett, Ph.D. 48,562,574 606,623 10,190,664 Michael Heffernan 43,518,474 5,650,723 10,190,664 Lisa Kelly-Croswell 43,651,100 5,518,097 10,190,664 Edward Mathers 32,479,275 16,689,922 10,190,664”

SYNLOGIC, INC. announced a restructuring with charges of approximately $0.9 million (approximately 21%).

“On June 5, 2023, Synlogic, Inc. (the “Company”) announced that it is implementing a reduction in workforce designed to focus resources on advancing the Company’s clinical stage programs and research activities that support the current clinical pipeline and its ongoing collaboration with Roche. The realignment is estimated to reduce the Company’s workforce by approximately 21%. The Company expects to complete substantially all of the reduction in workforce by the end of the fiscal quarter ending June 30, 2023. The Company estimates that it will incur approximately $0.9 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.”

SYNLOGIC, INC. reported first quarter ended March 31, 2023 results: revenue $0.2 million, net income consolidated net loss of $15.6 million, EPS $0.23 per share.

“partnerships Page 1 of 4 First Quarter 2023 Financial Results As of March 31, 2023, Synlogic had cash, cash equivalents and short-term investments of $57.4 million. Revenue was $0.2 million for each of the three months ended March 31, 2023 and March 31, 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the”

SYNLOGIC, INC. reported financial results for the quarter and full year ended December 31, 2022.

“On March 29, 2023, Synlogic, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2022.”

SYNLOGIC, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 6, 2022, Synlogic, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, (the “Common Stock”) for the last 30 consecutive business days, the Common Stock did not meet the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5450(a)(1), initiating an automatic 180 calendar-day grace period for the Company to regain compliance. The notice has no immediate effect on the listing or trading of the Company’s Common Stock”

SYNLOGIC, INC. announced a restructuring with charges of approximately $0.8 million (approximately 25% of its workforce).

“On November 28, 2022, the board of directors of Synlogic, Inc. (the “Company”), following a strategic review of its business, approved, and its management is implementing, a reduction in workforce, designed to focus resources on advancing the Company’s clinical stage programs and prioritized preclinical research programs. The realignment is estimated to reduce the Company’s workforce by approximately 25%. The Company estimates that it will incur approximately $0.8 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.”

SYNLOGIC, INC. amended Statement of Work with Azzur Cleanrooms-On-Demand – Boston, LLC valued at $1.7 million (effective 2022-11-22).

“On November 22, 2022, Synlogic Operating Company, Inc. (“Synlogic OpCo”), a wholly-owned subsidiary of Synlogic, Inc. (the “Company”), entered into a Statement of Work (the “SOW”) with Azzur Cleanrooms-On-Demand – Boston, LLC, (“Azzur”) pursuant to a License and Services Agreement (the “License Agreement”), effective as of April 28, 2021, by and between Synlogic OpCo and Azzur. Synlogic OpCo entered into an SOW with Azzur on January 21, 2022 (the “Previous SOW”). Pursuant to the Previous SOW, Synlogic OpCo was granted access to, and use of, the Azzur Suite for a period of 14 months, from January 2022 to March 2023. A copy of the Previous SOW is attached as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The SOW extends the term of the Previous SOW to cover the period beginning April 1, 2023 through December 31, 2023 (the “Term”). Synlogic OpCo retains the option to extend the Term twice, the first time through June 30, 2024 and subseq”

SYNLOGIC, INC. reported third quarter ended September 30, 2022 results: revenue $0.7 million, net income $17.9 million, EPS $0.25 per share.

“Revenue for the three months ended September 30, 2022 was $0.7 million compared to $0.9 million for the corresponding period in 2021. Revenue in both periods was associated with the ongoing research collaboration with Roche for the discovery of a novel Synthetic Biotic for the treatment of IBD. For the three months ended September 30, 2022, Synlogic reported a consolidated net loss of $17.9 million, or $0.25 per share, compared to a consolidated net loss of $16.0 million, or $0.29 per share, for the corresponding period in 2021.”

Michael Jensen was appointed as Chief Financial Officer at SYNLOGIC, INC..

“On March 3, 2022, Synlogic, Inc. (the “Company”) announced the appointment of Michael Jensen as Chief Financial Officer, effective March 3, 2022.”

Richard Riese departed as Chief Medical Officer at SYNLOGIC, INC..

“On July 29, 2021, Richard Riese, M.D., Ph.D., the Chief Medical Officer of Synlogic, Inc. (the "Company"), tendered his resignation.”